

## **Clinical Outcome Assessment — Initial Public Discussion**

In this presentation from C-Path's rare and orphan disease program, you will see an overview of patient-focused drug development and endpoints that inform regulatory decision making, a summary of work to date on concepts and tools, as well as next steps for engaging with people with lived experience.

[You can view the presentation slides here.](#)